Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03966248
Other study ID # DZM-KY201906
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 19, 2019
Est. completion date October 7, 2021

Study information

Verified date February 2023
Source Beijing University of Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Knee osteoarthritis (KOA) is one of the most common musculoskeletal diseases in clinic. It usually occurs in middle-aged people, especially women. An estimated lifetime risk for KOA is approximately 40% in men and 47% in women. KOA is a chronic disease which can lead to obvious pain, joint stiffness, limitation of activity and even disability, with significant associated costs and effects on society, health systems, and individuals. Tuina therapy has been used and showed effectiveness and safety for pain relief and disability for the patients with musculoskeletal disorders for years in China. Though it is regarded that the Traditional Chinese medicine (TCM) Tuina therapy is similar to the modern manual therapies, the modalities of TCM tuina therapy are different and effect maybe equal to or more better than the modern manual therapy in clinic. However, little evidence exists that Tuina benefits the KOA. The investigators will do this in a randomized, parallel, active controlled study to observe whether TCM Tuina is more beneficial to KOA than the physical manual therapy, which has been considered an effective and standard care for KOA.


Description:

Patients will be randomly allocated to one of two groups. In the Chinese Tuina group (group CTG), patients will receive the traditional Chinese Tuina therapy (including rolling, grasping, scratching, pressing, acupressure or pushing) on the basis of KOA health education and home-exercise. Patients in the Physical Manual group (group PMG) will receive the modern physical manual therapy (including joint mobilization/manipulation, manual traction, soft tissue manipulations, passive stretching, range of motion and strength training) on the basis of KOA health education and home-exercise. Assessments will be conducted at baseline and 4 and 16 weeks after randomization. It is expected that the interventions will alleviate the sufferings of the patient. The risks of participation are minimal. Occasionally, tuina can make people feel nauseous or experience a temporary increase in pain either during or after treatment. Rare side effects happen during and after Tuina or manual treatment.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date October 7, 2021
Est. primary completion date October 7, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. Diagnosis of KOA; 2. Age 40-75 years; 3. KL (Kellgren-Lawrence) grade ? or ? in recent 3 months; 4. NRS score of pain at least more than 4 points; 5. Single/bilateral knee pain, duration of more than 6 month; If the patient has KOA on both legs, the heavier leg is selected for study. Exclusion Criteria: 1. Surgery history of knee or waiting for surgery (knee replacement or knee arthroscopy); 2. Knee pain caused by other diseases (such as joint bodies, severe effusion of joint cavity, infection, malignant tumors, autoimmune diseases, trauma, etc.); 3. Oral administration of hormones within 3 month, intra-articular injection within 6 months, knee injuries or open injuries within 6 months, or knee arthroscopy within 1 year. 4. Severe acute/chronic organic or mental diseases; 5. Pregnant women, pregnant and lactating women; 6. Coagulation disorders (such as hemophilia, etc.), or the skin diseases at the site of operation; 7. Device support treatment after knee osteoarthritis disability; 8. Participation in another clinical study in the past 3 months; 9. History of receiving acupuncture, massage, manipulation, or any medical plaster treatment within 3 months 10. Breaks for treatment longer than 3-4 weeks depending on each circumstance or merit may be construed as non-compliance and may be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chinese Tuina therapy
The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle; The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb; Massage the spleen and stomach meridians of the affected lower extremes; Roll the soft tissues around the affected knee; Relax the gastrocnalis muscle The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time; Push the patella and do the passive movement of the affected knee; Strength training of the affected knee. This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
Physical Manual therapy
Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa. Activity training: Mainly about the knee joint flexion and extension movement training. Strength training: Mainly about quadriceps muscle resistance exercises This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.

Locations

Country Name City State
China Dongzhimen hospital affiliated to Bejing University of Chinese Medicine Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing University of Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Self report measure of pain, stiffness, and physical function for people with knee osteoarthritis. Change from baseline at 4 weeks
Secondary Change in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Self report measure of pain, stiffness, and physical function for people with knee osteoarthritis. Change from baseline at 8 weeks and 16 weeks
Secondary Change in Numeric Knee Pain Rating Scale Subjects will rate their worst knee pain in the last 24 hours using an 11 point numeric pain rating scale with 0 representing "no pain" and 10 representing " the worst pain imaginable". Change from baseline at 4 weeks, 8 weeks and 16 weeks
Secondary Change in Patient Global Assessment (PGA) The Patient global assessment rating is a 11 point Numeric Rating Scale in which subjects will rate the degree to which their knee condition has changed from the time treatment was initiated to the present. The subject responds to the following query: "Please rate your overall knee's condition from the time you began treatment until now." using an 11 point numeric rating scale with 0 representing "A very great deal better" and 10 representing "A very great deal worse". Change from baseline at 4 weeks, 8 weeks and 16 weeks
Secondary Change in 12-item Short Form Health Survey (SF-12) The SF-12 is a generic health-related quality of life measure. Change from baseline at 4 weeks, 8 weeks and 16 weeks
Secondary Change in 30 second time chair rise test Subjects will be seated with their arms crossed in front of their chest. On the command "go" subjects will stand up and sit down for as many trials as they can in a 30 second period. Change from baseline at 4 weeks
Secondary Change in Timed Up and Go Test Time On the command "go" subjects will stand up from a chair, walk 3 meters, turn around, return to the chair and sit down. The time it takes to complete this task will be recorded. Change from baseline at 4 weeks
Secondary Change in One Leg Standing Test One single-leg standing was assessed balance. Test required the subject to stand with arms by his/her side.Timing was started when the subject raised one foot off the ground. Timing was stopped if the subject displaced the weight-bearing foot, touched the suspended foot to the ground, used the suspended limb to support the weight-bearing limb, or reached the maximum balance time of 30 seconds. Change from baseline at 4 weeks
Secondary OARSI Responder Criteria Responder criteria included 1) greater than or equal to 50% improvement in WOMAC pain or WOMAC function and an absolute improvement of greater than or equal to 20, or 2) improvement in at least 2 of the following 3 scores: 20% improvement in pain and absolute change = 10 on WOMAC pain score, 20% improvement in pain and absolute change = 10 on WOMAC function score, or moderate or greater improvement (= 4) on a 15 point global rating of change scale At weeks 4 after randomisation.
Secondary Blinding assessment To test whether the participants are blinded successfully, all participants will be asked to guess which kind of treatment they received. At weeks 4 after randomisation.
Secondary Credibility/Expectancy Questionnaire The credibility and expectancy of participants will be measured using the Credibility/Expectancy Questionnaire About 5 min after the first treatment
Secondary Rescue medicine Any use of pain-killers will be ascertained. At weeks 4, 8 and 16 after randomisation.
Secondary Adverse events Adverse Event Form At weeks 4 after randomisation.
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Not yet recruiting NCT02826850 - Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial Phase 3
Not yet recruiting NCT02865174 - Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty Phase 4
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2